HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].

AbstractINTRODUCTION:
Piribedil is a D2 D3 dopamine agonist, which has been shown to be well tolerated and to improve Parkinsonian symptoms, particularly tremor. However, few studies have been published about this Dopamine Agonist as an adjunct to levodopa therapy in patients with Parkinson's disease (PD). This placebo controlled, parallel group study was undertaken to investigate the effects of piribedil in PD patients insufficiently controlled with levodopa in a nine months follow up.
PATIENTS AND METHODS:
We included 62 PD patients insufficiently controlled with levodopa and needed an increase in dopamine stimulation. Patients were randomized in two similar groups, one of them taking Piribedil and levodopa and the other group taking a placebo and levodopa. The primary efficacy measures were the items II and III of the UPDRS. The patients were evaluated prior to the start of therapy, and 3, 6 and 9 months after the start of the study.
RESULTS:
Patients taking Piribedil showed an average of improvement of 37,8% (p < 0.01) in the part II and 63,2% (p < 0.01) in the part III of the UPDRS at the end of the study. At 9 month evaluation, tremor at rest showed an average improvement of 68,6%, rigidity, fingers taps and legs agility improved substantially in their respective items of the UPDRS at the end of the study.
CONCLUSIONS:
We concluded that PD patients with functional worsening while on stable levodopa doses exhibit a steady improvement of the UPDRS part II and III with the adjunction of Piribedil 150 mg mean daily dose for 9 months.
AuthorsG Salazar Tortolero, R Wix Ramos, P Salazar Aladrén, J C Jiménez León
JournalRevista de neurologia (Rev Neurol) 2004 Apr 16-30 Vol. 38 Issue 8 Pg. 715-9 ISSN: 0210-0010 [Print] Spain
Vernacular TitleEficacia y tolerancia del piribedil como terapia adjunta a la levodopa en pacientes con enfermedad de Parkinson: seguimiento de nueve meses.
PMID15122540 (Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial)
Chemical References
  • Antiparkinson Agents
  • Dopamine Agonists
  • Levodopa
  • Piribedil
Topics
  • Antiparkinson Agents (administration & dosage, adverse effects, therapeutic use)
  • Dopamine Agonists (administration & dosage, adverse effects, therapeutic use)
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Gastrointestinal Diseases (chemically induced)
  • Humans
  • Levodopa (administration & dosage, therapeutic use)
  • Male
  • Middle Aged
  • Muscle Rigidity (drug therapy)
  • Parkinson Disease (drug therapy)
  • Piribedil (administration & dosage, adverse effects, therapeutic use)
  • Treatment Outcome
  • Tremor (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: